Skip to main content
SpringerLink
Log in

Assessment of men’s risk thresholds to proceed with prostate biopsy for the early detection of prostate cancer

  • Urology - Original Paper
  • Published:
International Urology and Nephrology Aims and scope Submit manuscript

Abstract

Purpose

To delineate the range of “risk thresholds” for prostate biopsy to determine how improved prostate cancer (CaP) risk prediction tools may impact shared decision-making (SDM).

Methods

We conducted a cross-sectional survey study involving men 45–75 years old attending a multispecialty urology clinic. Data included demographics, personal and family prostate cancer history, and prostate biopsy history. Respondents were presented with a summary of the details, risks, and benefits of prostate biopsy, then asked to indicate the specific risk threshold (% chance) of high-grade CaP at which they would proceed with prostate biopsy.

Results

Of a total of 103 respondents, 18 men (17%) had a personal history of CaP, and 31 (30%) had undergone prostate biopsy. The median risk threshold to proceed with prostate biopsy was 25% (interquartile range 10–50%). Risk thresholds did not vary by race, education, or employment. Personal history of CaP or prostate biopsy was significantly associated with lower mean risk thresholds (19% vs. 32% [P = 0.02] and 23% vs. 33% [P = 0.04], respectively). In the lowest versus highest risk threshold quartiles, there were significantly higher rates of CaP (36% vs. 1%, P = 0.01) and prior prostate biopsy (46% vs. 17%, P < 0.01).

Conclusions

Men have a wide range of risk thresholds for high-grade CaP to proceed with prostate biopsy. Men with a prior history of CaP or biopsy reported lower risk thresholds, which may reflect their greater concern for this disease. The extent to which refined risk prediction tools will improve SDM warrants further study.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Carter HB, Albertsen PC, Barry MJ, Etzioni R, Freedland SJ, Greene KL et al (2013) Early detection of prostate cancer: AUA guideline. J Urol 190(2):419–426. https://doi.org/10.1016/j.juro.2013.04.119

    Article  PubMed  PubMed Central  Google Scholar 

  2. Thompson IM Jr, Leach RJ, Ankerst DP (2014) Focusing PSA testing on detection of high-risk prostate cancers by incorporating patient preferences into decision making. JAMA 312(10):995–996. https://doi.org/10.1001/jama.2014.9680

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Ankerst DP, Boeck A, Freedland SJ, Jones JS, Cronin AM, Roobol MJ et al (2014) Evaluating the prostate cancer prevention trial high grade prostate cancer risk calculator in ten international biopsy cohorts: results from the Prostate Biopsy Collaborative Group. World J Urol 32(1):185–191. https://doi.org/10.1007/s00345-012-0869-2

    Article  PubMed  Google Scholar 

  4. Benchikh A, Savage C, Cronin A, Salama G, Villers A, Lilja H et al (2010) A panel of kallikrein markers can predict outcome of prostate biopsy following clinical work-up: an independent validation study from the European Randomized Study of Prostate Cancer Screening, France. BMC Cancer 10:635. https://doi.org/10.1186/1471-2407-10-635

    Article  PubMed  PubMed Central  Google Scholar 

  5. Gupta A, Roobol MJ, Savage CJ, Peltola M, Pettersson K, Scardino PT et al (2010) A four-kallikrein panel for the prediction of repeat prostate biopsy: data from the European Randomized Study of Prostate Cancer screening in Rotterdam, Netherlands. Br J Cancer 103(5):708–714. https://doi.org/10.1038/sj.bjc.6605815

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Vickers A, Cronin A, Roobol M, Savage C, Peltola M, Pettersson K et al (2010) Reducing unnecessary biopsy during prostate cancer screening using a four-kallikrein panel: an independent replication. J Clin Oncol 28(15):2493–2498. https://doi.org/10.1200/JCO.2009.24.1968

    Article  PubMed  PubMed Central  Google Scholar 

  7. Loeb S, Catalona WJ (2014) The Prostate Health Index: a new test for the detection of prostate cancer. Ther Adv Urol 6(2):74–77. https://doi.org/10.1177/1756287213513488

    Article  PubMed  PubMed Central  Google Scholar 

  8. Nordstrom T, Vickers A, Assel M, Lilja H, Gronberg H, Eklund M (2015) Comparison between the four-kallikrein panel and prostate health index for predicting prostate cancer. Eur Urol 68(1):139–146. https://doi.org/10.1016/j.eururo.2014.08.010

    Article  CAS  PubMed  Google Scholar 

  9. Chiu PK, Roobol MJ, Teoh JY, Lee WM, Yip SY, Hou SM et al (2016) Prostate health index (PHI) and prostate-specific antigen (PSA) predictive models for prostate cancer in the Chinese population and the role of digital rectal examination-estimated prostate volume. Int Urol Nephrol 48(10):1631–1637. https://doi.org/10.1007/s11255-016-1350-8

    Article  PubMed  Google Scholar 

  10. Ng CF, Chiu PK, Lam NY, Lam HC, Lee KW, Hou SS (2014) The Prostate Health Index in predicting initial prostate biopsy outcomes in Asian men with prostate-specific antigen levels of 4–10 ng/mL. Int Urol Nephrol 46(4):711–717. https://doi.org/10.1007/s11255-013-0582-0

    Article  CAS  PubMed  Google Scholar 

  11. Alford AV, Brito JM, Yadav KK, Yadav SS, Tewari AK, Renzulli J (2017) The use of biomarkers in prostate cancer screening and treatment. Rev Urol 19(4):221–234. https://doi.org/10.3909/riu0772

    Article  PubMed  PubMed Central  Google Scholar 

  12. Kornberg Z, Cooperberg MR, Spratt DE, Feng FY (2018) Genomic biomarkers in prostate cancer. Transl Androl Urol 7(3):459–471. https://doi.org/10.21037/tau.2018.06.02

    Article  PubMed  PubMed Central  Google Scholar 

  13. Kearns JT, Lin DW (2018) Improving the specificity of PSA screening with serum and urine markers. Curr Urol Rep 19(10):80. https://doi.org/10.1007/s11934-018-0828-6

    Article  PubMed  Google Scholar 

  14. Eskra JN, Rabizadeh D, Pavlovich CP, Catalona WJ, Luo J (2019) Approaches to urinary detection of prostate cancer. Prostate Cancer Prostatic Dis. https://doi.org/10.1038/s41391-019-0127-4

    Article  PubMed  PubMed Central  Google Scholar 

  15. Schmid M, Trinh QD, Graefen M, Fisch M, Chun FK, Hansen J (2014) The role of biomarkers in the assessment of prostate cancer risk prior to prostate biopsy: which markers matter and how should they be used? World J Urol 32(4):871–880. https://doi.org/10.1007/s00345-014-1317-2

    Article  CAS  PubMed  Google Scholar 

  16. Lee DJ, Mallin K, Graves AJ, Chang SS, Penson DF, Resnick MJ et al (2017) Recent changes in prostate cancer screening practices and epidemiology. J Urol 198(6):1230–1240. https://doi.org/10.1016/j.juro.2017.05.074

    Article  Google Scholar 

  17. Sayyid RK, Dingar D, Fleshner K, Thorburn T, Diamond J, Yao E et al (2017) What false-negative rates of non-invasive testing are active surveillance patients and uro-oncologists willing to accept in order to avoid prostate biopsy? Can Urol Assoc J 11(3–4):118–122. https://doi.org/10.5489/cuaj.4182

    Article  PubMed  PubMed Central  Google Scholar 

  18. Roumiguie M, Beauval JB, Bordier B, Filleron T, Rozet F, Ruffion A et al (2015) What risk of prostate cancer led urologist to recommend prostate biopsies? Prog Urol 25(16):1125–1131. https://doi.org/10.1016/j.purol.2015.08.007

    Article  CAS  PubMed  Google Scholar 

  19. Bioreference Laboratories (2017) 4Kscore results interpretation and test characteristics reference card. https://4kscore.com/4kscore-test-for-physicians/physicians-booklet/. Accessed 5 Feb 2019

  20. Mottet N, van den Bergh RCN, Briers E, Cornford P, Santis MD, Fanti S et al (2019) EAU guidelines: prostate cancer. https://uroweb.org/guideline/prostate-cancer/#5. Accessed 3 Jun 2019

  21. Foley RW, Maweni RM, Gorman L, Murphy K, Lundon DJ, Durkan G et al (2016) European Randomised Study of Screening for Prostate Cancer (ERSPC) risk calculators significantly outperform the Prostate Cancer Prevention Trial (PCPT) 2.0 in the prediction of prostate cancer: a multi-institutional study. BJU Int 118(5):706–713. https://doi.org/10.1111/bju.13437

    Article  PubMed  Google Scholar 

  22. Loeb S, Shin SS, Broyles DL, Wei JT, Sanda M, Klee G et al (2017) Prostate Health Index improves multivariable risk prediction of aggressive prostate cancer. BJU Int 120(1):61–68. https://doi.org/10.1111/bju.13676

    Article  CAS  PubMed  Google Scholar 

  23. Dijkstra S, Govers TM, Hendriks RJ, Schalken JA, Van Criekinge W, Van Neste L et al (2017) Cost-effectiveness of a new urinary biomarker-based risk score compared to standard of care in prostate cancer diagnostics—a decision analytical model. BJU Int 120(5):659–665. https://doi.org/10.1111/bju.13861

    Article  PubMed  Google Scholar 

  24. Voigt JD, Dong Y, Linder V, Zappala S (2017) Use of the 4Kscore test to predict the risk of aggressive prostate cancer prior to prostate biopsy: overall cost savings and improved quality of care to the us healthcare system. Rev Urol 19(1):1–10

    PubMed  PubMed Central  Google Scholar 

  25. Koo K, Brackett CD, Eisenberg EH, Kieffer KA, Hyams ES (2017) Impact of numeracy on understanding of prostate cancer risk reduction in PSA screening. PLoS One 12(12):e0190357. https://doi.org/10.1371/journal.pone.0190357

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Gokce MI, Wang X, Frost J, Roberson P, Volk RJ, Brooks D et al (2017) Informed decision making before prostate-specific antigen screening: initial results using the American Cancer Society (ACS) Decision Aid (DA) among medically underserved men. Cancer 123(4):583–591. https://doi.org/10.1002/cncr.30367

    Article  PubMed  Google Scholar 

  27. Arterburn D, Wellman R, Westbrook EO, Ross TR, McCulloch D, Handley M et al (2015) Decision aids for benign prostatic hyperplasia and prostate cancer. Am J Manag Care 21(2):e130–e140

    PubMed  Google Scholar 

  28. Holmes-Rovner M, Montgomery JS, Rovner DR, Scherer LD, Whitfield J, Kahn VC et al (2015) Informed decision making: assessment of the quality of physician communication about prostate cancer diagnosis and treatment. Med Decis Making 35(8):999–1009. https://doi.org/10.1177/0272989X15597226

    Article  PubMed  Google Scholar 

  29. Huntley JH, Coley RY, Carter HB, Radhakrishnan A, Krakow M, Pollack CE (2018) Clinical evaluation of an individualized risk prediction tool for men on active surveillance for prostate cancer. Urology 121:118–124. https://doi.org/10.1016/j.urology.2018.08.021

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Section of Urology, Department of Surgery, Dartmouth-Hitchcock Medical Center, Lebanon, NH, USA

    Kevin Koo & Elias S. Hyams

  2. Department of Urology, Johns Hopkins University School of Medicine, 600 North Wolfe Street, Baltimore, MD, 21287, USA

    Kevin Koo

Authors
  1. Kevin Koo
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Elias S. Hyams
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Kevin Koo.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional research committee and with the 1964 Helsinki declaration.

Informed consent

Informed consent was obtained from all individual participants included in the study.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary material 1 (DOCX 16 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Koo, K., Hyams, E.S. Assessment of men’s risk thresholds to proceed with prostate biopsy for the early detection of prostate cancer. Int Urol Nephrol 51, 1297–1302 (2019). https://doi.org/10.1007/s11255-019-02196-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11255-019-02196-0

Keywords

Search

Navigation